Clinical Trial Update: Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dexamethasone followed by denileukin diftitox in persistent or recurrent T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Lymphoma

Drugs mentioned

• Denileukin diftitox (Ontak) (denileukin diftitox)
• Dexamethasone (Decadron) (dexamethasone)

Snippet

Sponsor: Ligand Pharmaceuticals | Conditions: Drug/Agent Toxicity by Tissue/Organ, Lymphoma | Phase 2 | Status: COMPLETED